The Pi Picos are tiny but capable, once you get used to their differences.

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

What is Grok? Explore Elon Musk’s AI chatbot with real-time X data, bold personality, advanced features, pricing, risks, and ...

News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

・Analysts estimate about 116% upside for REPL, compared to a 124% upside for IOVA from current levels. ・Amtagvi, already approved for melanoma, helped Iovance generate about $264 million in product ...

Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all ...

Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...